Page last updated: 2024-11-04

alpha-isopropylmalate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-isopropylmalic acid: chelates aluminum(III); structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

2-isopropylmalic acid : A dicarboxylic acid that is malic acid (2-hydroxysuccinic acid) in which the hydrogen at position 2 is substituted by an isopropyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

alpha-isopropylmalate: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

(2S)-2-isopropylmalic acid : An optically active form of 2-isopropylmalic acid having S-configuration. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

2-isopropylmalate : A dicarboxylic acid anion obtained by deprotonation of at least one of the carboxy groups of 2-isopropylmalic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID77
CHEBI ID28635
SCHEMBL ID59972
MeSH IDM0047768
PubMed CID5280523
CHEBI ID35128
SCHEMBL ID1409965
MeSH IDM0047768

Synonyms (65)

Synonym
alpha-isopropylmalic acid
2-hydroxy-2-(1-methylethyl)butanedioic acid
CHEBI:28635
3-carboxy-3-hydroxyisocaproic acid
3237-44-3
2-hydroxy-2-(propan-2-yl)butanedioic acid
2-hydroxy-2-isopropylsuccinic acid
3-carboxy-3-hydroxy-4-methylpentanoic acid
butanedioic acid, 2-hydroxy-2-(1-methylethyl)
2-isopropylmalic acid
2-isopropylmalic acid, 98%
CD7B7575-5C65-4347-9BAC-D899775FC34D
malic acid, 2-isopropyl-
2-hydroxy-2-propan-2-ylbutanedioic acid
BMSE000982
BMSE001025
a7t9uy4kvu ,
unii-a7t9uy4kvu
SCHEMBL59972
beta-hydroxy-beta-carboxy-isocaproic acid
2-hydroxy-2-isopropylsuccinicacid
butanedioic acid, 2-hydroxy-2-(1-methylethyl)-
J-018719
AKOS030570175
Q15426256
F83120
HY-N9960
CS-0226996
SB84200
DTXSID70863129
AS-81339
.alpha.-isopropylmalate
alpha-ipm
(3s)-3-carboxy-3-hydroxyisocaproic acid
49601-06-1
(2s)-2-hydroxy-2-(propan-2-yl)butanedioic acid
(3s)-3-carboxy-3-hydroxy-4-methylpentanoic acid
(s)-2-hydroxy-2-(isopropyl)succinic acid
CHEBI:35128
(2s)-2-isopropylmalic acid
C02504
3-carboxy-3-hydroxy-4-methylpentanoate
(2s)-2-isopropylmalate
alpha-isopropylmalate
3-carboxy-3-hydroxyisocaproate
(2s)-2-hydroxy-2-isopropylsuccinic acid
2-isopropylmalate
(2s)-2-isopropyl-2-hydroxy-butanedioic acid
2-isopropyl-malic acid
LMFA01170083
unii-3m4xt3p3yc
2-isopropylmalic acid, (s)-(+)-
3m4xt3p3yc ,
einecs 256-395-7
SCHEMBL1409965
2-isopropyl-2-hydroxybutanedioic acid
2-isopropyl-2-hydroxybutanedioate
a-isopropylmalate
a-isopropylmalic acid
DTXSID201021196
(s)-2-hydroxy-2-isopropylsuccinic acid
(s)-(+)-2-isopropylmalic acid
(2s)-2-hydroxy-2-(1-methylethyl)butanedioic acid
butanedioic acid, 2-hydroxy-2-(1-methylethyl)-, (s)-
butanedioic acid, 2-hydroxy-2-(1-methylethyl)-, (2s)-
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
dicarboxylic acidAny carboxylic acid containing two carboxy groups.
3-hydroxy carboxylic acidAny hydroxy carboxylic acid which contains a hydroxy group located beta- to the carboxylic acid group.
2-hydroxy carboxylic acid
2-isopropylmalic acidA dicarboxylic acid that is malic acid (2-hydroxysuccinic acid) in which the hydrogen at position 2 is substituted by an isopropyl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (3)

PathwayProteinsCompounds
Leucine Biosynthesis816
Secondary Metabolites: Valine and L-Leucine Biosynthesis from Pyruvate1024
Secondary Metabolites: Leucine Biosynthesis716

Research

Studies (29)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (20.69)18.7374
1990's5 (17.24)18.2507
2000's9 (31.03)29.6817
2010's6 (20.69)24.3611
2020's3 (10.34)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.14

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.14 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.62 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.14)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
Other18 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]